{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-099121","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.564381+00:00","generated_at":"2026-05-31T05:13:58.853536+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events","bullets":["VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.","PK results showed dose-dependent exposure of VYN202 in plasma and urine across all doses tested.","PD activity observed: increased HEXIM1 (target engagement) and inhibitory effect on inflammatory biomarkers for psoriasis and rheumatoid arthritis.","Dosing in the multiple ascending dose (MAD) portion of Phase 1a has begun; results expected Q4 2024.","CEO David Domzalski highlighted milestone for the company's BD2-selective BET inhibitor platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-099121","json":"https://secwatch.observer/filing/0001104659-24-099121.json","markdown":"https://secwatch.observer/filing/0001104659-24-099121.md","text":"https://secwatch.observer/filing/0001104659-24-099121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924099121/0001104659-24-099121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924099121/tm2423851d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:13:58.853536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}